



cancers



an Open Access Journal by MDPI

Checkpoint Markers and Cancer Microenvironment: What Do We Know?

Guest Editor:

Prof. Dr. Vasso Apostolopoulos

Institute for Health and Sport,
Victoria University, Melbourne,
VIC 3011, Australia

Deadline for manuscript
submissions:

closed (31 March 2023)

Message from the Guest Editor

Dear Colleagues,

Inhibitory checkpoint molecules are targets for cancer immunotherapy due to their potential for use in multiple types of cancer. Immune checkpoint blockade has vastly changed the landscape of cancer treatment and has shown a promising prognosis for cancer patients. However, the majority of patients will not benefit from immune checkpoint inhibitor therapy (innate resistance), and a substantial proportion of the responding patients will progress while on treatment (acquired resistance). Therefore, it is essential to investigate biomarkers to predict the efficacy of immune checkpoint inhibitors. In this Special Issue, we hope to collect papers on checkpoint markers for different cancers. We hope that this will promote study in this field.

Prof. Dr. Vasso Apostolopoulos
Guest Editor



mdpi.com/si/126480

Special Issue



cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI